Literature DB >> 9264358

Angiogenesis in endometrial carcinoma.

T Kaku1, T Kamura, N Kinukawa, H Kobayashi, K Sakai, N Tsuruchi, T Saito, S Kawauchi, M Tsuneyoshi, H Nakano.   

Abstract

BACKGROUND: Tumor angiogenesis is essential for tumor growth and metastases. Recently, microvessel density (MVD), a measure of tumor angiogenesis, has been found to have prognostic significance for predicting metastasis and survival in many tumor types. This study was conducted to determine how MVD was related to several clinicopathologic parameters and correlated with metastasis and survival in patients with endometrial carcinoma.
METHODS: From 1979 through 1989, 85 cases of clinical Stage I and II endometrial carcinomas treated initially by hysterectomy with pelvic lymph node dissection were reviewed histologically. All hysterectomy specimens were stained immunohistologically for factor VIII-related antigen. MVD was counted in a x200 field (x20 objective lens and x10 ocular lens, 0.785 mm2 per field) in the most active area of neovascularization. Results were expressed as the highest number of microvessels identified within any single x200 field. Statistical analysis included the Mann-Whitney U test, Kruskal-Wallis test of variance, and the Spearman rank correlation test. Survival was calculated using the Kaplan-Meier method and differences in survival were analyzed using the log rank test. MVD and several other prognostic parameters were examined for their correlation with progression free survival (PFS) and overall survival (OS) by a multivariate analysis according to the Cox proportional hazards model.
RESULTS: MVD was significantly correlated with tumor grade (P = 0.0281), myometrial invasion (P = 0.0282), and lymph-vascular space invasion (P = 0.0073). There was no correlation between microvessel count and lymph node status and stage. Patients with a high MVD (> or =60) had significantly worse PFS and OS than those with a low MVD (<60) (log rank test, P = 0.0116 and P = 0.0096, respectively). Multivariate analysis showed that MVD correlated significantly and independently with PFS and OS.
CONCLUSIONS: In this study, MVD was found to be an independent prognostic factor for PFS and OS in patients with endometrial carcinoma.

Entities:  

Mesh:

Year:  1997        PMID: 9264358     DOI: 10.1002/(sici)1097-0142(19970815)80:4<741::aid-cncr13>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  Targeting angiogenesis in gynecologic cancers.

Authors:  Behrouz Zand; Robert L Coleman; Anil K Sood
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

2.  Altered expression of transcription factor Sp1 critically impacts the angiogenic phenotype of human gastric cancer.

Authors:  Liwei Wang; Xiaohong Guan; Weida Gong; James Yao; Zhihai Peng; Daoyan Wei; Tsung-Teh Wu; Suyun Huang; Keping Xie
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma.

Authors:  Ying Liu; Haiyan Li; Congying Zhao; Hanbing Jia
Journal:  Mol Cell Biochem       Date:  2018-02-05       Impact factor: 3.396

4.  Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma.

Authors:  Qi Shen; Melissa L Stanton; Wei Feng; Michelle E Rodriguez; Lois Ramondetta; Lei Chen; Robert E Brown; Xiuzhen Duan
Journal:  Int J Clin Exp Pathol       Date:  2010-11-20

5.  Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.

Authors:  Robert A Burger
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

6.  Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86).

Authors:  Neesha C Dhani; Hal W Hirte; Lisa Wang; Julia V Burnier; Angela Jain; Marcus O Butler; Stephen Welch; Gini F Fleming; Jean Hurteau; Koji Matsuo; Daniela Matei; Waldo Jimenez; Carolyn Johnston; Mihaela Cristea; Katia Tonkin; Prafull Ghatage; Stephanie Lheureux; Anjali Mehta; Judy Quintos; Qian Tan; Suzanne Kamel-Reid; Olga Ludkovski; Ming-Sound Tsao; John J Wright; Amit M Oza
Journal:  Clin Cancer Res       Date:  2020-01-28       Impact factor: 12.531

7.  Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas.

Authors:  O Bairey; Y Zimra; E Kaganovsky; M Shaklai; E Okon; E Rabizadeh
Journal:  Med Oncol       Date:  2000-11       Impact factor: 3.064

8.  Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab.

Authors:  Beom-Su Jang; Sang-Myung Lee; Hyung Sub Kim; In Soo Shin; Faezeh Razjouyan; Shutao Wang; Zhengsheng Yao; Ira Pastan; Matthew R Dreher; Chang H Paik
Journal:  Nucl Med Biol       Date:  2011-12-14       Impact factor: 2.408

9.  IL-8 up-regulates proliferative angiogenesis in ischemic myocardium in rabbits through phosphorylation of Akt/GSK-3β(ser9) dependent pathways.

Authors:  Qiying Xie; Zelin Sun; Meifang Chen; Qiaoqing Zhong; Tianlun Yang; Jun Yi
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 10.  Therapeutic advances in women's cancers.

Authors:  Amy R Carroll; Robert L Coleman; Anil K Sood
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.